RxDoctor Payments DataLook up a doctor →

Matthew Baker, MD

Neurology · Naples, FLNPI 1154372167

Payments from drug & device makers

$5,425,558in general payments, 2019–2025

Across 2,570 payments — averaging $2111.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2.7M
  • Sanofi$335K
  • Adamas Pharmaceuticals, Inc.$304K
  • EMD Serono, Inc.$290K
  • Biogen$283K
  • AstraZeneca$228K
  • plus $1.3M from 54 others
$5,475in research payments, 2019–2025

Across 18 payments — averaging $304.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$3K
  • EMD Serono, Inc.$1K
  • Sanofi$660

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis133$2,732,570
Sanofi182$334,510
Adamas Pharmaceuticals, Inc.64$303,983
EMD Serono, Inc.281$289,880
Biogen294$283,249
AstraZeneca(2 entities)290$228,428
Amgen(2 entities)38$197,431
Modernatx, Inc.43$127,456
AbbVie(2 entities)235$120,097
TG Therapeutics, Inc.79$119,198
E.r. Squibb & Sons, L.L.C.81$102,121
Otsuka America Pharmaceutical, Inc.100$90,560
Alkermes, Inc.28$74,582
H. Lundbeck A S19$73,086
Mallinckrodt Hospital Products Inc.62$69,969
Genentech USA, Inc.72$52,255
Avanir Pharmaceuticals, Inc.75$49,292
Janssen Research & Development, LLC7$42,026
Bristol Myers Squibb72$30,427
Teva Pharmaceuticals USA, Inc.58$22,053
Pfizer19$19,653
Biohaven Pharmaceutical Holding Company Ltd.13$17,671
Biohaven Pharmaceuticals, Inc.20$11,158
Mallinckrodt Enterprises LLC8$11,138
Argenx US, Inc.24$6,983
Ares Trading SA15$4,204
Genentech, Inc.5$3,589
Alnylam Pharmaceuticals Inc.18$1,484
Banner Life Sciences, LLC3$945
UCB, Inc.29$944
Acadia Pharmaceuticals Inc27$489
Eisai Inc.20$476
Lilly USA, LLC24$417
GE HealthCare22$365
Lundbeck LLC7$294
SK Life Science, Inc.4$293
Acorda Therapeutics, Inc12$250
Sunovion Pharmaceuticals Inc.9$223
Neurelis, Inc.8$208
Sumitomo Pharma America, Inc.3$169
Johnson & Johnson(2 entities)11$161
Neurocrine Biosciences, Inc.5$132
Vanda Pharmaceuticals Inc.5$106
Kyowa Kirin, Inc.5$101
Harmony Biosciences LLC3$97
Amneal Pharmaceuticals LLC5$85
MDD US Operations, LLC4$82
Cvrx, Inc.1$79
Scilex Pharmaceuticals Inc.3$70
Greenwich Biosciences, Inc.2$63
Merz Pharmaceuticals, LLC2$55
Catalyst Pharmaceuticals, Inc.2$45
Tanabe Pharma America, Inc.3$44
Octapharma USA, Inc.2$38
Medtronic(2 entities)2$36
Takeda Pharmaceuticals U.S.A., Inc.1$35
Xeris Pharmaceuticals, Inc.2$33
Sanofi-aventis U.S. LLC2$32
Novocure Inc.1$29
Merz North America, Inc.1$24

How this compares

$5,425,558 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida →

Medicare billing

Part B allowed, 2024
$4,233,276
Medicare patients
609
Services billed
67,711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Naples

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →